P187 Hearing loss in patients with Inflammatory Bowel Disease
B. Koslowsky*1, H. Shaul2, U. Peleg2, L. Cohen3, M. Gross3, D. Wengrower1
1Shaare Zedek Medical Center, Gastroenterology, Jerusalem, Israel, 2Shaare Zedek Medical Center, Department of Otorhinolaryngology, Jerusalem, Israel, 3Hadassah Medical Center, Department of Otorhinolaryngology, Jerusalem, Israel
Inflammatory bowel disease (IBD) has many characteristics of autoimmune diseases. Sensorineural hearing loss has been reported in many autoimmune diseases. Little is known about hearing loss in patients with IBD.
A prospective blinded comparative study was conducted over a 3 year period. IBD patients and controls underwent a complete otorhinolaryngeal examination and eudiometry test. Any participant with current or past use of an ototoxic medication or recurrent ear infections was excluded from the study.
Altogether 105 participants (76 patients and 29 controls) took part in this study. 59 (77%) had Crohn's disease (CD) and 17 (23%) had ulcerative colitis (UC). Mean age was 36 ± 13, 51% were males and 40% of the patients were presently hospitalized due to IBD exacerbation. 16/76(21%) of the IBD patients complained of any hearing loss since IBD diagnosis and 13% had current hearing disabilities. Audiometric examination revealed that any hearing loss (mild to severe) was found in 23 (30%) of the IBD population, compared to 3 (10%) of the control group (p<0.05). Sensironeural was the hearing deficiency type in 93% of them. Out of 46 patients, whose extraintestinal manifestation (EIM) status was clearly documented, 43% (n=20) had EIMs. Hearing loss was present in 5/20 (25%) of these patients, compared to 0/23 who did not have EIMs (p<0.01). IBD phenotype (inflammatory vs. obstructive/fistulary), current hospitalization and disease type (CD vs. UC) was not significantly different between these groups.
Sensironeural hearing loss may be another EIM of IBD. It is found in 30% of IBD patients, and in up to 43% of patients who have other EIMs. Early hearing evaluation should be recommended to IBD patients who have other EIMs. Ototoxic hazards should be avoided in IBD patients.